This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 169 entries.
Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance. The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap […]
Euroz Hartleys has published a research note on Botanix forecasting strong sales momentum for Sofdra™. Click here to read the report.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
The Australian Financial Review has featured Botanix as an ASX favourite. In an article profiling stock picks by Liam Donohue from Lennox Capital, he assessed the market opportunity for Sofdra™: ‘…current treatments have been more invasive (such as targeted Botox injections) and typically less effective. ‘So, with many of the more binary risks out of […]
Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso. Read article
First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025. View release.
Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release. View ASX release.
Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives. View release.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product. View Report.
While in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months. Take a look:
